JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Higashi, K.
Right arrow Articles by Yamamoto, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Higashi, K.
Right arrow Articles by Yamamoto, I.
Journal of Nuclear Medicine Vol. 43 No. 1 39-45
© 2002 by Society of Nuclear Medicine

Clinical Investigations

18F-FDG Uptake as a Biologic Prognostic Factor for Recurrence in Patients with Surgically Resected Non–Small Cell Lung Cancer

Kotaro Higashi, MD1, Yoshimichi Ueda, MD2, Yukiko Arisaka, MD1, Tsutomu Sakuma, MD3, Yoshihiro Nambu, MD4, Manabu Oguchi, MD1, Hiroyasu Seki, MD5, Suzuka Taki, MD1, Hisao Tonami, MD1 and Itaru Yamamoto, MD1

1 Department of Radiology, Kanazawa Medical University, Ishikawa, Japan
2 Department of Pathology, Kanazawa Medical University, Ishikawa, Japan
3 Department of Respiratory Surgery, Kanazawa Medical University, Ishikawa, Japan
4 Division of Respiratory Disease, Department of Internal Medicine, Kanazawa Medical University, Ishikawa, Japan
5 Department of Radiology, Kanazawa Cardiovascular Hospital, Ishikawa, Japan

Among patients with resected non–small cell lung cancer (NSCLC), approximately 50% present with a recurrent tumor. The clinical or pathologic TNM staging does not always provide a satisfactory explanation for differences in relapse and survival. Thus, it is of major importance to be able to predict these relapses and to prevent them with an active chemotherapy or radiotherapy program (or both). 18F-FDG uptake on PET could be of prognostic significance in patients with resected NSCLC. The goal of this study was to determine whether the level of metabolic activity observed with 18F-FDG uptake correlates with the probability of postoperative recurrence in patients with NSCLC. Methods: Fifty-seven patients with NSCLC were examined with 18F-FDG PET. For semiquantitative analysis, standardized uptake values (SUVs) were calculated. Patients were classified into high-SUV (>5.0) and low-SUV (<=5.0) groups. All patients underwent thoracotomy within 4 wk after the 18F-FDG PET study. Tumor 18F-FDG uptake (SUV), pathologic stage, and lesion size were analyzed for their possible association with disease-free survival. Results: Forty-six patients had pathologic stage I NSCLC and 11 had pathologic stage II or stage III NSCLC. In a univariate analysis, patients with an SUV of <=5 had a much better disease-free survival than did patients with an SUV of >5 (P < 0.0001). In patients with pathologic stage I and stage IA NSCLC, the SUV was also correlated with disease-free survival (P < 0.0001 and P = 0.0012, respectively). Patients with pathologic stage I disease had an expected 5-y disease-free survival rate of 88% if the SUV was <=5 and a survival rate of <=17% if the SUV was >5. A multivariate Cox analysis identified the SUV as the most significant independent factor for disease-free survival. Conclusion: We conclude that the 18F-FDG uptake in primary NSCLC determined by PET has a significant independent postoperative prognostic value for recurrence, especially in patients with pathologic stage I NSCLC. 18F-FDG uptake was superior to pathologic stage in predicting relapse of patients with NSCLC.

Key Words: PET • 18F-FDG • lung cancer • disease-free survival




This article has been cited by other articles:


Home page
 RadiologyHome page
M. C. B. Godoy and D. P. Naidich
Subsolid Pulmonary Nodules and the Spectrum of Peripheral Adenocarcinomas of the Lung: Recommended Interim Guidelines for Assessment and Management
Radiology, December 1, 2009; 253(3): 606 - 622.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Jadvar, A. Alavi, and S. S. Gambhir
18F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization
J. Nucl. Med., November 1, 2009; 50(11): 1820 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. J. Erasmus, E. Rohren, and S. G. Swisher
Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging
Proceedings of the ATS, April 15, 2009; 6(2): 171 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
N. Kanauchi, H. Oizumi, T. Honma, H. Kato, M. Endo, J. Suzuki, K. Fukaya, and M. Sadahiro
Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer
Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 706 - 711.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
H. R. Kim, D.-J. Kim, W. W. Lee, S. Jheon, and S. W. Sung
The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma
Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 712 - 717.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
N. Al-Sarraf, K. Gately, J. Lucey, R. Aziz, K. Doddakula, L. Wilson, E. McGovern, and V. Young
Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases
Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 892 - 897.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
F.-X. Hanin, M. Lonneux, J. Cornet, P. Noirhomme, C. Coulon, J. Distexhe, and A. J. Poncelet
Prognostic value of FDG uptake in early stage non-small cell lung cancer
Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 819 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Ueda, H. Tsuda, H. Asakawa, T. Shigekawa, K. Fukatsu, N. Kondo, M. Yamamoto, Y. Hama, K. Tamura, J. Ishida, et al.
Clinicopathological and Prognostic Relevance of Uptake Level using 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging (18F-FDG PET/CT) in Primary Breast Cancer
Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 250 - 258.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. K. Hoang, L. F. Hoagland, R. E. Coleman, A. D. Coan, J. E. Herndon II, and E. F. Patz Jr
Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non-Small-Cell Lung Carcinoma
J. Clin. Oncol., March 20, 2008; 26(9): 1459 - 1464.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. C. Lee, J. L. Port, R. J. Korst, Y. Liss, D. N. Meherally, and N. K. Altorki
Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
Ann. Thorac. Surg., July 1, 2007; 84(1): 177 - 181.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. J. Downey, T. Akhurst, M. Gonen, B. Park, and V. Rusch
Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1419 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, J. D. Freeman, L. Wiens, J. Stern, H. Q. Nguyen, S. E. Hawes, P. Bastian, A. Salskov, E. Vallieres, and D. E. Wood
Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role
Clin. Cancer Res., June 1, 2007; 13(11): 3255 - 3263.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. J. Raz, A. Y. Odisho, B. L. Franc, and D. M. Jablons
Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1189 - 1195.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. de Geus-Oei, B Wiering, P. Krabbe, T. Ruers, C. Punt, and W. Oyen
FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma
Ann. Onc., November 1, 2006; 17(11): 1650 - 1655.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Cerfolio and A. S. Bryant
Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study
Ann. Thorac. Surg., August 1, 2006; 82(2): 424 - 430.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Prevost, L. Boucher, P. Larivee, R. Boileau, and F. Benard
Bone Marrow Hypermetabolism on 18F-FDG PET as a Survival Prognostic Factor in Non-Small Cell Lung Cancer
J. Nucl. Med., April 1, 2006; 47(4): 559 - 565.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Guo, K. Higashi, Y. Ueda, M. Oguchi, T. Takegami, H. Toga, T. Sakuma, H. Yokota, S. Katsuda, H. Tonami, et al.
Microvessel Density: Correlation with 18F-FDG Uptake and Prognostic Impact in Lung Adenocarcinomas
J. Nucl. Med., March 1, 2006; 47(3): 419 - 425.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
V. Kalff, C. Duong, E. G. Drummond, J. P. Matthews, and R. J. Hicks
Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery
J. Nucl. Med., January 1, 2006; 47(1): 14 - 22.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. J. Cerfolio, A. S. Bryant, B. Ohja, and A. A. Bartolucci
The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival
J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 151 - 159.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. K. Shankar and D. C. Sullivan
Functional Imaging in Lung Cancer
J. Clin. Oncol., May 10, 2005; 23(14): 3203 - 3211.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Sasaki, R. Komaki, H. Macapinlac, J. Erasmus, P. Allen, K. Forster, J. B. Putnam, R. S. Herbst, C. A. Moran, D. A. Podoloff, et al.
[18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 20, 2005; 23(6): 1136 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. Higashi, K. Ito, Y. Hiramatsu, T. Ishikawa, T. Sakuma, I. Matsunari, G. Kuga, K. Miura, T. Higuchi, H. Tonami, et al.
18F-FDG Uptake by Primary Tumor as a Predictor of Intratumoral Lymphatic Vessel Invasion and Lymph Node Involvement in Non-Small Cell Lung Cancer: Analysis of a Multicenter Study
J. Nucl. Med., February 1, 2005; 46(2): 267 - 273.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. Hellwig, T. P. Graeter, D. Ukena, T. Georg, C.-M. Kirsch, and H.-J. Schafers
Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
J. Thorac. Cardiovasc. Surg., December 1, 2004; 128(6): 892 - 899.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Schrevens, N. Lorent, C. Dooms, and J. Vansteenkiste
The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer
Oncologist, November 1, 2004; 9(6): 633 - 643.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Downey, T. Akhurst, M. Gonen, A. Vincent, M. S. Bains, S. Larson, and V. Rusch
Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection
J. Clin. Oncol., August 15, 2004; 22(16): 3255 - 3260.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Guo, K. Higashi, H. Yokota, Y. Nagao, Y. Ueda, Y. Kodama, M. Oguchi, S. Taki, H. Tonami, and I. Yamamoto
In Vitro Proton Magnetic Resonance Spectroscopic Lactate and Choline Measurements, 18F-FDG Uptake, and Prognosis in Patients with Lung Adenocarcinoma
J. Nucl. Med., August 1, 2004; 45(8): 1334 - 1339.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, E. Turcotte, L. Wiens, R. Schmidt, J. E. Takasugi, T. Lalani, E. Vallieres, and D. E. Wood
Relationship between Non-Small Cell Lung Cancer Fluorodeoxyglucose Uptake at Positron Emission Tomography and Surgical Stage with Relevance to Patient Prognosis
Clin. Cancer Res., July 15, 2004; 10(14): 4709 - 4716.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 JNMHome page
B. G.M. Durie, A. D. Waxman, A. D'Agnolo, and C. M. Williams
Whole-Body 18F-FDG PET Identifies High-Risk Myeloma
J. Nucl. Med., November 1, 2002; 43(11): 1457 - 1463.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.